Lexeo Therapeutics (LXEO) Long-Term Investments (2024 - 2026)

Lexeo Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Long-Term Investments fell 51.81% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 51.81% YoY) and the FY2025 annual result came in at $64.8 million, up 824.14% from the prior year.
• Long-Term Investments declined to $3.4 million in Q1 2026 per LXEO's latest filing, from $64.8 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $64.8 million in Q4 2025 and troughed at $3.4 million in Q2 2025.
• A 3-year average of $14.8 million and a median of $5.2 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Investments jumped 824.14% in 2025, then plunged 51.81% in 2026.
• Over 3 years, Long-Term Investments stood at $7.0 million in 2024, then surged by 824.14% to $64.8 million in 2025, then sank by 94.77% to $3.4 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $3.4 million, $64.8 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.